| Evolution de l'incidence et de la mortalité du cancer pulmonaire en Suisse: explications possibles et questions ouvertes | |  | | 2025 | 48 | 122 |
|
| Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC : From Bedside to Bench and Back | BioDrugs | | | 2025 | 56 | 973 |
|
| The Landscape of Immunotherapy Resistance in NSCLC | Frontiers in oncology | | | 2022 | 144 | 290 |
|
